Profile
mDETECT offers highly sensitive and cost-effective blood tests that can measure tumour behaviour irrespective of cancer type, stage, or context to aid in determining therapy response, resistance, and recurrence monitoring. This aims to empower clinicians to make informed treatment decisions, identify responders, optimize drug selection, and minimize exposure to ineffective therapies, ultimately improving patient outcomes.
mDETECT's core technology, Methylation Detection of Circulating Tumour DNA (ctDNA), utilizes targeted next-generation sequencing (NGS) of patented DNA methylated regions specific to cancer patients, allowing for precise and quantitative measurement of tumour burden. mDETECT has developed and validated six liquid biopsies covering breast, prostate, lung, pancreatic, ovarian and colorectal cancers. The tests are high throughput, cost effective, have a quick turnaround time, are tissue naïve and can be performed in the hospital.
Event details
Event contact
Participants
-
20/20 OptimEyes Technologies has developed a mucoadhesive drug delivery platform technology that allows for… -
Since 2001, BioScript Solutions has supported patients with chronic illnesses and rare diseases by providing… -
Custom Biologics provides regulatory compliant potency testing and assay services for all phases of… -
Dalriada is a leading North American discovery company pioneering its novel Turn-Key™ model in small molecule… -
HDAX Therapeutics, a biotechnology company pioneering a novel approach to target HDAC6 to address… -
ImmunoBiochem is an innovative biopharmaceutical company developing novel bioconjugate therapeutics, such … -
Invest Ontario is a provincial agency dedicated to securing private sector strategic business and capital… -
Raising capital is a key challenge for executives at early-stage therapeutics companies. Lumerate is launching… -
mDETECT offers highly sensitive and cost-effective blood tests that can measure tumour behaviour irrespective of… -
Noa Therapeutics is a preclinical biotech company pioneering the development of homeostatic modulating small… -
Nucro-Technics is a full-service Contract Support Organization that specializes in the conduct of both GLP… -
Paradox Immunotherapeutics is a biotech addressing the global burden of protein misfolding diseases—devastating… -
ProteinQure has built the best computational platform for designing peptides for extra-cellular targets. Its lead… -
QReserve provides powerful enterprise-grade scheduling and resource management software to world-class… -
Specific Biologics is developing Dualase®, an industry-leading genome editing platform with best-in-class… -
Spiderwort is a platform biomaterials company developing a suite of cellulose-based scaffolds for use in a number… -
Stiris is a clinical trial management company conducting Phase I-IIIB trials for biotech and… -
Sussex Research Laboratories Inc. (Ottawa, Canada) is recognized as a leader in the design and synthesis of… -
SYNG Pharma is developing a new first-in-class diagnostic test and non-hormonal therapy for endometriosis. The… -
Transpharmation is a contract research organisation led by scientists. Recognised by drug developers worldwide… -
VeriLuce Therapeutics is an early-stage drug company developing novel small molecules targeting in dual… -
Virano is a genetic immunomodulation company, developing next-generation combination products which reprogram the… -
YYZ Pharmatech Inc. (“YYZ”) is a deep tech company endeavoring to profoundly progress…